In DEREG mice where the DT was administered at day 0 or 5 (sensitization phase of AIA), IFN-α could still significantly mitigate arthritis as compared with control DEREG mice receiving DT day 0 or day 5, respectively (Figure 1B). Here, IFNA1 is linked to arthritic joint disease.